DSIP or Emideltide After the July 2026 PCAC Review: What the Evidence Shows
DSIP or Emideltide After the July 2026 PCAC Review: What the Evidence Shows
Editorial disclosure: Generic Peptides sells peptides for laboratory research. This article explains a public regulatory proceeding and is not medical or legal advice. Emideltide, also known as DSIP, is not FDA-approved for insomnia, narcolepsy, opioid withdrawal, or any other medical use.
Few peptide names make a stronger promise than delta sleep-inducing peptide. Usually shortened to DSIP, the name suggests a substance that switches on deep, slow-wave sleep. That simple story has followed the peptide since the 1970s—and has proved difficult to confirm.
The FDA's Pharmacy Compounding Advisory Committee (PCAC) reviewed emideltide free base and emideltide acetate on July 24, 2026. The committee did not give these substances a positive recommendation for inclusion on the Section 503A Bulks List. The recommendation is advisory, not an FDA approval or a final agency determination. It does not itself add either form to the list or authorize compounding. Final regulatory action remains with FDA.
FDA identifies emideltide as the substance commonly called DSIP. The nominated uses were chronic insomnia, narcolepsy, and opioid withdrawal. Those uses came from the compounding nomination process; they are not FDA findings that emideltide treats any of the three conditions.
For broader context, see our July 2026 FDA peptide meeting guide, plus our related BPC-157 FDA review, TB-500 FDA review, and MOTS-c FDA review.
DSIP and Emideltide Are Two Names for the Same Peptide
DSIP is the historical name. Emideltide is the name FDA uses in its briefing materials. The substance is reported to be a nine-amino-acid peptide with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, often written as WAGGDASGE.
The peptide was first isolated from rabbit blood during experiments involving sleep. Early work connected it with changes in electroencephalogram (EEG) activity, including delta-wave patterns associated with deep non-REM sleep. That observation explains the name, but it does not establish that DSIP is a master sleep signal or a reliable insomnia treatment.
Researchers have continued to debate where DSIP is produced, whether it has a specific receptor, and how directly it controls sleep. A 2006 review described it as a "still unresolved riddle."
The regulatory distinction is also important. FDA's briefing document states that emideltide free base and emideltide acetate are different bulk drug substances. It notes inconsistent information in the withdrawn nominations, no applicable USP or NF monograph, and no FDA-approved drug containing either form. For product specifications and available documentation, see the DSIP research peptide page.
Why Were Three Different Conditions Nominated?
Chronic insomnia, narcolepsy, and opioid withdrawal are not three versions of the same disorder.
Chronic insomnia involves persistent difficulty falling asleep, staying asleep, or obtaining restorative sleep. Narcolepsy is a disorder of sleep-wake regulation that can cause severe daytime sleepiness and sudden sleep attacks. Opioid withdrawal is a physiological response to reducing or stopping opioids after dependence has developed.
DSIP entered all three discussions because early researchers proposed that it might regulate disturbed sleep, stress responses, and endogenous opioid systems. That broad hypothesis is scientifically interesting, but each indication requires separate evidence.
An insomnia treatment should improve sleep and daytime function. A narcolepsy treatment must address excessive daytime sleepiness without worsening nighttime sleep. An opioid-withdrawal treatment must be evaluated in a medically serious setting where relapse, reduced tolerance, dehydration, pregnancy, and polysubstance use can change risk.
What the Human Studies Actually Show
Unlike many newer research peptides, DSIP has been administered to people in published studies. Most of that research is old, small, and heterogeneous.
An early 1981 study examined synthetic DSIP in six healthy volunteers. Other studies in the 1980s described injections in people with insomnia or disturbed sleep. One open report involved seven patients with severe insomnia who received ten injections. Reports described changes in sleep latency, sleep efficiency, awakenings, or slow-wave sleep.
A 1992 double-blind study enrolled 16 people with chronic insomnia. Some objective sleep measurements favored DSIP, but the authors described the statistically significant effects as weak and concluded that short-term treatment was unlikely to provide major therapeutic benefit.
The narcolepsy evidence is narrower still. A 1984 report described repeated injections in one 35-year-old man and reported fewer sleep attacks and improved daytime alertness. A single case can generate a hypothesis; it cannot establish effectiveness or uncommon risks.
Withdrawal evidence also comes mainly from uncontrolled reports. A 1983 paper described intravenous DSIP in people withdrawing from alcohol or opioids. The analysis included only part of the enrolled group and had no modern randomized comparison. A later open trial reported DSIP during opioid detoxification, but the record never developed into a convincing, replicated clinical program.
These studies show historical human exposure. They do not establish a validated modern treatment protocol for emideltide free base or emideltide acetate.
Why the Age and Design of the Evidence Matter
An old study is not automatically a bad study. The problem is that the DSIP literature did not mature into a consistent drug-development program.
The published reports use different preparations, routes, sample sizes, endpoints, and safety descriptions. Many were produced by a small research community, and several appeared in a 1984 issue of European Neurology devoted heavily to DSIP-related work.
Since then, sleep-disorder definitions, polysomnography, narcolepsy biology, opioid-withdrawal care, trial standards, and adverse-event reporting have all advanced. A promising open study from the 1980s cannot carry the same weight as a modern, adequately powered, independently replicated randomized trial.
What FDA Identified as Missing
FDA's emideltide briefing evaluates the exact bulk substances, their characterization, historical use, effectiveness evidence, and safety. FDA states that the nominations were withdrawn but that the agency evaluated the substances on its own initiative.
The briefing identifies several problems:
- inconsistent descriptions of whether the nominated material was free base or acetate;
- limited physical and chemical characterization;
- no applicable USP or NF monograph;
- insufficient evidence of effectiveness for the proposed subcutaneous route;
- lack of route-specific clinical safety data;
- potential immunogenicity and peptide-impurity concerns; and
- uncertainty about formulating the proposed 1,000 mcg/mL injectable product.
FDA also notes that historical studies involved different preparations and, in several cases, intravenous administration. Those results cannot automatically answer the safety question for a specific free-base or acetate substance used by a different route.
FDA's conclusion is not that DSIP has been proven dangerous. It is that the available characterization, effectiveness, and safety information is insufficient, and that the evaluation criteria weigh against adding either emideltide form to the 503A Bulks List.
What the July PCAC Recommendation Means
The committee's negative recommendation is an important regulatory development, but it is still advisory. PCAC provides scientific advice to FDA; it does not issue drug approvals and cannot by itself amend the 503A Bulks List.
The result should therefore be described precisely:
- emideltide/DSIP was reviewed by PCAC on July 24, 2026;
- the committee did not support a positive recommendation for the nominated substances;
- the recommendation is non-binding;
- neither form became FDA-approved;
- neither form was automatically added to the 503A Bulks List; and
- final action remains with FDA.
The outcome also does not establish a dose, route, formulation, or clinical indication. It does not convert historical studies into evidence that research products are suitable for human use.
The Three Indications Must Stay Separate
The insomnia, narcolepsy, and opioid-withdrawal nominations should not be merged into a single claim that DSIP "improves sleep." The conditions have different biology, outcome measures, risks, and standards of care.
Evidence from a small insomnia study does not establish benefit in narcolepsy. A single narcolepsy case does not establish treatment for the wider population. Uncontrolled withdrawal reports cannot substitute for randomized evidence in a high-risk clinical setting.
That separation is central to interpreting the PCAC outcome. A peptide can have historical exposure and intriguing mechanisms while still lacking the evidence needed for a specific compounded drug product.
The Bottom Line
DSIP is not a modern peptide with no human history. People received DSIP-related preparations in sleep and withdrawal studies decades ago. That history is exactly why the substance attracted regulatory attention.
But the record remains fragmented. The studies are small, old, inconsistent, and difficult to connect to a precisely characterized modern product. FDA also identified route-specific safety and characterization gaps.
The July 24, 2026 PCAC review did not produce a positive recommendation for emideltide free base or emideltide acetate. That is not FDA approval, not automatic 503A Bulks List inclusion, and not proof that DSIP treats insomnia, narcolepsy, or opioid withdrawal. It is an advisory step in a process whose final decision remains with FDA.
Sources
- FDA: July 23–24, 2026 Meeting of the Pharmacy Compounding Advisory Committee
- FDA: Briefing Document for Emideltide-Related Bulk Drug Substances
- FDA: Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks
- FDA PrecisionFDA/GSRS: Emideltide Substance Record
- Schoenenberger G.A. et al.: The Delta EEG Sleep-Inducing Peptide, 1977
- Kovalzon V.M. and Strekalova T.V.: Delta Sleep-Inducing Peptide: A Still Unresolved Riddle, 2006
- Schneider-Helmert D. and Schoenenberger G.A.: Acute and Delayed Effects of DSIP on Human Sleep, 1981
- Kaeser H.E.: A Clinical Trial With DSIP, 1984
- Bes F. et al.: Effects of DSIP on Sleep of Chronic Insomniac Patients, 1992
- Schneider-Helmert D.: Effects of DSIP on Narcolepsy, 1984
- Dick P. et al.: Treatment of Withdrawal Symptoms With Delta Sleep-Inducing Peptide, 1983
- Backmund M. et al.: Opioid Detoxification With DSIP, 1998